Immunotherapy study for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a wearable biosensor can track how patients with advanced lung cancer respond to immunotherapy drugs like pembrolizumab, atezolizumab, or nivolumab. It aims to find new ways to monitor treatment and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage IIIB or IV (advanced and has spread).
- You are receiving immunotherapy (pembrolizumab, atezolizumab, or nivolumab) with or without chemotherapy.
- You must be able to wear a small biosensor bracelet on your wrist.
- Your overall health status allows for light activity (WHO performance status less than 2).
- You are able to understand English and give full consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial is for people with stage IIA to IIIB non-small cell lung cancer that can be removed by surgery. It tests if certain white blood cells (neutrophils) can help predict how well chemotherapy combined with immunotherapy works before surgery.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial checks whether a device called TheraSure CNI-Monitor can be used while people with advanced lung cancer receive immunotherapy. It aims to improve monitoring during palliative (comfort-focused) treatment.
This study is looking at immune markers in people with advanced non-small cell lung cancer (NSCLC) that cannot be cured. It tests how well the immune system responds to treatment, and may help guide future care.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.